MA35125B1 - Alpha glucosidase acide modifiee a traitement accelere - Google Patents

Alpha glucosidase acide modifiee a traitement accelere

Info

Publication number
MA35125B1
MA35125B1 MA36431A MA36431A MA35125B1 MA 35125 B1 MA35125 B1 MA 35125B1 MA 36431 A MA36431 A MA 36431A MA 36431 A MA36431 A MA 36431A MA 35125 B1 MA35125 B1 MA 35125B1
Authority
MA
Morocco
Prior art keywords
alpha acid
accelerated treatment
acid glucosidase
modified
treatment
Prior art date
Application number
MA36431A
Other languages
English (en)
Inventor
William M Canfield
Rodney J Moreland
Mariko Kudo
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35125(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA35125B1 publication Critical patent/MA35125B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un polypeptide d'alpha-glucosidase acide humaine modifiée à hydrophobicité améliorée en position 201 de la seq no: 1, ainsi que des procédés de préparation et d'utilisation de l'alpha-glucosidase acide humaine modifiée dans le traitement de troubles de stockage glycogène.
MA36431A 2011-04-22 2013-11-14 Alpha glucosidase acide modifiee a traitement accelere MA35125B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22
PCT/US2012/034479 WO2012145644A1 (fr) 2011-04-22 2012-04-20 Alpha-glucosidase acide modifiée à traitement accéléré

Publications (1)

Publication Number Publication Date
MA35125B1 true MA35125B1 (fr) 2014-05-02

Family

ID=46000406

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36431A MA35125B1 (fr) 2011-04-22 2013-11-14 Alpha glucosidase acide modifiee a traitement accelere

Country Status (24)

Country Link
US (1) US20140186326A1 (fr)
EP (1) EP2699676A1 (fr)
JP (2) JP2014513952A (fr)
KR (1) KR20140037082A (fr)
CN (1) CN103797115A (fr)
AU (1) AU2012245280A1 (fr)
BR (1) BR112013026976A2 (fr)
CA (1) CA2833371A1 (fr)
CL (1) CL2013003010A1 (fr)
CO (1) CO6811810A2 (fr)
CR (1) CR20130555A (fr)
EC (1) ECSP13013036A (fr)
GT (1) GT201300252A (fr)
IL (1) IL228871A0 (fr)
MA (1) MA35125B1 (fr)
MX (1) MX2013012345A (fr)
NI (1) NI201300110A (fr)
PE (1) PE20140617A1 (fr)
PH (1) PH12013502149A1 (fr)
RU (1) RU2013151875A (fr)
SG (2) SG194486A1 (fr)
TN (1) TN2013000427A1 (fr)
WO (1) WO2012145644A1 (fr)
ZA (1) ZA201307696B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130723A1 (fr) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Méthodes et compositions pour le traitement de la maladie de pompe
CN114540327B (zh) 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
MX2018005258A (es) 2015-11-06 2019-09-04 Biomarin Pharm Inc Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas.
KR102747683B1 (ko) * 2015-12-30 2024-12-31 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase
JP7046003B2 (ja) 2016-03-30 2022-04-01 アミカス セラピューティックス インコーポレイテッド 高ｍ６ｐ組換えタンパク質の選択方法
EP3293203A1 (fr) 2016-09-12 2018-03-14 Genethon Variants d'alpha-glucosidase acide et leurs utilisations
EP3293260A1 (fr) 2016-09-12 2018-03-14 Genethon Variants d'alpha-glucosidase acide et leurs utilisations
EP3293259A1 (fr) 2016-09-12 2018-03-14 Genethon Variants d'alpha-glucosidase acide et leurs utilisations
PE20191203A1 (es) 2016-09-12 2019-09-10 Genethon Variantes de alfa-glucosidasa acida y usos de las mismas
ES2950808T3 (es) 2017-05-15 2023-10-13 Amicus Therapeutics Inc Alfa-glucosidasa ácida humana recombinante
ES3065816T3 (en) 2017-06-07 2026-05-08 Regeneron Pharma Compositions and methods for internalizing enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
JP7771045B2 (ja) 2019-07-09 2025-11-17 ジェネトン 糖原病（ｇｓｄ）の処置
PH12022551229A1 (en) * 2019-11-19 2023-07-31 Asklepios Biopharmaceutical Inc Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US6066626A (en) 1997-10-29 2000-05-23 Genzyme Corporation Compositions and method for treating lysosomal storage disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
CA2353522A1 (fr) 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Traitement de la maladie de pompe
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
WO2003045928A1 (fr) 2001-11-26 2003-06-05 Genzyme Corporation Synthese diastereoselective d'udp-glucose : inhibiteurs de la n-acylsphingosine glucosyltransferase
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
JP5433133B2 (ja) * 2003-01-22 2014-03-05 デューク・ユニヴァーシティ リソソームポリペプチドを発現するための改善された構築物
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
BRPI0411843B8 (pt) 2003-06-24 2021-05-25 Genzyme Corp ácido nucleico compreendendo um promotor de beta-actina, vetor e método de produzir uma proteína
CA2553955C (fr) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Alpha-glucosidase acide et fragments de celle-ci
CA2669347A1 (fr) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methodes de traitement de la maladie de pompe
PL2889043T3 (pl) 2008-12-16 2019-09-30 Genzyme Corporation Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko
US8466340B2 (en) * 2009-02-18 2013-06-18 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Also Published As

Publication number Publication date
RU2013151875A (ru) 2015-05-27
JP2014513952A (ja) 2014-06-19
KR20140037082A (ko) 2014-03-26
BR112013026976A2 (pt) 2019-09-24
ZA201307696B (en) 2014-07-30
MX2013012345A (es) 2015-05-07
SG194486A1 (en) 2013-12-30
NI201300110A (es) 2014-02-28
PH12013502149A1 (en) 2019-09-02
IL228871A0 (en) 2013-12-31
US20140186326A1 (en) 2014-07-03
CA2833371A1 (fr) 2012-10-26
TN2013000427A1 (en) 2015-03-30
EP2699676A1 (fr) 2014-02-26
CO6811810A2 (es) 2013-12-16
AU2012245280A1 (en) 2013-11-07
PE20140617A1 (es) 2014-05-28
JP2017035091A (ja) 2017-02-16
CL2013003010A1 (es) 2014-03-07
SG10201605874TA (en) 2016-09-29
WO2012145644A1 (fr) 2012-10-26
GT201300252A (es) 2015-02-09
CR20130555A (es) 2013-12-09
ECSP13013036A (es) 2015-04-30
CN103797115A (zh) 2014-05-14

Similar Documents

Publication Publication Date Title
MA38276B1 (fr) Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
PH12013501089A1 (en) Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
BR112013030894A2 (pt) moduladores do sistema imune
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
EP2418945A4 (fr) Compositions de sel minéral/acide sulfonique et procédés d'utilisation
BR112013026114A2 (pt) composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
MA33899B1 (fr) Procedes et regimes a faible dose pour des troubles des globules rouges
MA33299B1 (fr) Nouvelle formulation de naproxène
HK1218836A1 (zh) 协同细菌组合物和其制造方法和用途
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
BR112015007616A2 (pt) inibidores de mek no tratamento de doenças por vírus
MA45504A1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
BR112013028420A2 (pt) tratamento de mieloma múltiplo
MX336715B (es) Purificacion de iduronato-2-sulfatasa.
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
CR20150196A (es) Moléculas de unión il-17a novedosas y usos médicos de las mismas